Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Frederik Giesel

Gallium 68 PSMA-11 PET/MR Imaging in Patients With Intermediate- Or High-Risk Prostate Cancer

Radiology

English

The Future of Radioligand Therapy: Α, Β, or Both?

Journal of Nuclear Medicine

English

Related publications

18F Fluorocholine Dynamic Time-Of-Flight PET/MR Imaging in Patients With Newly Diagnosed Intermediate- To High-Risk Prostate Cancer: Initial Clinical-Pathologic Comparisons

English

Immunohistochemical Validation of PSMA-expression Measured by 68 Ga-Psma PET/CT in Primary Prostate Cancer

Journal of Nuclear Medicine

English

Optimization of PET Protocol and Interrater Reliability of 18f-Psma-11 Imaging of Prostate Cancer

English

Comparison of [18F]DCFPyL and [68Ga]Ga-Psma-Hbed-Cc for PSMA-PET Imaging in Patients With Relapsed Prostate Cancer

Molecular Imaging and Biology

English

(OA35) Impact of Staging 68Ga-Psma-11 Pet Scans on Radiation Treatment Plans in Patients With Prostate Cancer

International Journal of Radiation Oncology Biology Physics

English

Diagnostic Performance of 68Ga-Psma-11 (HBED-CC) PET/CT in Patients With Recurrent Prostate Cancer: Evaluation in 1007 Patients

European Journal of Nuclear Medicine and Molecular Imaging

English

Actual Impact Of68Ga-Psma-11 PET/CT on the Management of Prostate Cancer Patients With Biochemical Recurrence

Journal of Nuclear Medicine

English

Comparison of 68Ga-Psma-11 PET/CT With 11c-Acetate PET/CT in Re-Staging of Prostate Cancer Relapse

Scientific Reports

Multidisciplinary

2020

English

Correction To: Randomized Prospective Phase III Trial of 68Ga-Psma-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning [PSMA-SRT]

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Frederik Giesel

Gallium 68 PSMA-11 PET/MR Imaging in Patients With Intermediate- Or High-Risk Prostate Cancer

The Future of Radioligand Therapy: Α, Β, or Both?

Related publications

18F Fluorocholine Dynamic Time-Of-Flight PET/MR Imaging in Patients With Newly Diagnosed Intermediate- To High-Risk Prostate Cancer: Initial Clinical-Pathologic Comparisons

Immunohistochemical Validation of PSMA-expression Measured by 68 Ga-Psma PET/CT in Primary Prostate Cancer

Optimization of PET Protocol and Interrater Reliability of 18f-Psma-11 Imaging of Prostate Cancer

Comparison of [18F]DCFPyL and [68Ga]Ga-Psma-Hbed-Cc for PSMA-PET Imaging in Patients With Relapsed Prostate Cancer

(OA35) Impact of Staging 68Ga-Psma-11 Pet Scans on Radiation Treatment Plans in Patients With Prostate Cancer

Diagnostic Performance of 68Ga-Psma-11 (HBED-CC) PET/CT in Patients With Recurrent Prostate Cancer: Evaluation in 1007 Patients

Actual Impact Of68Ga-Psma-11 PET/CT on the Management of Prostate Cancer Patients With Biochemical Recurrence

Comparison of 68Ga-Psma-11 PET/CT With 11c-Acetate PET/CT in Re-Staging of Prostate Cancer Relapse

Correction To: Randomized Prospective Phase III Trial of 68Ga-Psma-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning [PSMA-SRT]